Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES)
ConclusionRoxadustat was non-inferior to ESAs in maintaining hemoglobin levels in this cohort of patients with anemia of CKD on dialysis for at least 4 months who were previously treated with ESAs. Observed TEAEs were consistent with previous studies.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Anemia | Aranesp | Cholesterol | Chronic Kidney Disease | Dialysis | Drugs & Pharmacology | Epogen | Headache | Hypertension | Migraine | Procrit | Study | Thrombosis | Urology & Nephrology